Article

Inequality in Kidney Cancer Treatment Affects Decision-Making

Author(s):

The risk for under- or over-treatment for kidney cancer may be higher in women, in addition to Black and Hispanic patients.

Demographic factors including sex, race/ethnicity and insurance status may influence whether a patient is under- or overtreated for localized kidney cancer, according to a study.

“Despite the increasing attention devoted to overtreatment of indolent malignant tumors in urologic oncology, many patients with aggressive disease are undertreated, particularly members of racial/ethnic minority groups,” the study authors wrote.

Kidney cancer is among the 10 most common cancers in both men and women, according to the American Cancer Society. Black patients are twice as likely to have kidney cancer compared with other patients. Overall, it is predicted that there will be about 76,080 (48,780 men and 27,300 women) new cases of kidney cancer diagnosed in 2021.

Researchers used data collected between 2010 and 2017 to assess whether patients received non-guideline-based treatment for kidney cancer.

“We sought to assess the association between demographic factors (including sex, race/ethnicity and insurance status) and receipt of non-guideline–based kidney cancer treatmentin a comparatively young and healthy (group) of patients with localized kidney cancer and low competing risk of mortality,” the study authors wrote.

Among the 158,445 patients (median age, 58 years) with kidney cancer enrolled in the study, 62.8% were men, 75.7% were White and 57.6% had private insurance. In addition, 30.6% of patients received non-guideline-based treatment.

Compared with men, women were less likely to be undertreated for kidney cancer and more likely to be overtreated. Black and Hispanic patients were more likely to be undertreated and overtreated for kidney cancer compared with White patients.

Patients without insurance were more likely to be undertreated and less likely to be overtreated for kidney cancer compared with patients who had insurance.

“Clinicians should bear these disparities in mind when counseling individual patients, and health policy makers should take the existence of these disparities into account,” the study authors wrote.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content